![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
AGIRx Ltd. |
---|---|
Information provided by: | AGIRx Ltd. |
ClinicalTrials.gov Identifier: | NCT00716495 |
In this open-label study of patients with advanced melanoma 20 evaluable patients will be recruited.
The drug substance, AGI-101H, is a whole cell, allogeneic melanoma vaccine, representing a mixture (1:1 ratio) of two therapeutic gene modified human melanoma cell lines, referred to as Mich1H6 and Mich2H6, which has been gamma-irradiated to render the cells non-proliferative
Patients will receive treatment for up to 26 weeks. Progression at any time point requiring systemic treatment with, for example with chemotherapy or cytokines will lead to withdrawal of this patient from the study.
The dose chosen is 5 x 107 viable cells/dose.
Condition | Intervention | Phase |
---|---|---|
Melanoma |
Biological: AGI-101H Vaccine |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Single Group Assignment, Safety Study |
Official Title: | A Phase I/IIa, Open-Label Bridging Safety and Pharmacodynamic Study of a New Formulation of 6 Month Extended Dosing With AGI - 101H Vaccine in the Treatment of Patients With Advanced Melanoma |
Estimated Enrollment: | 20 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | March 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Total number of patients: 20 evaluable patients will be enrolled in the study.
Dosage: 5 x 107 live cells. No dose modification is planned.
Administration: Subcutaneous (s.c.)
Duration of treatment: Patients will receive treatment for up to 26 weeks. Progression at any time point requiring systemic treatment with, for example with chemotherapy or cytokines will lead to withdrawal of this patient from the study. All surviving patients of this AGITAM trial will be offered the opportunity to transfer to a follow-up treatment protocol with AGI - 101H. In this case treatment may continue every 4 - 8 weeks until progression or death or withdrawal unless such therapy is contraindicated or patient does not wish to continue.
Reference therapy: Not applicable.
Description of medicinal product: The drug substance, AGI-101H, is a whole cell, allogeneic melanoma vaccine, representing a mixture (1:1 ratio) of two therapeutic genemodified human melanoma cell lines, referred to as Mich1H6 and Mich2H6, which has been gamma-irradiated to render the cells non-proliferative. There is no recommended International Non-proprietary (INN) Name for the drug substance.
Methodology: In this open-label study of patients with advanced melanoma, one dose of AGI - 101H vaccine will be administered s.c.. 20 evaluable patients will be recruited. An independent data monitoring committee (DMC) will review all safety data after the first 10 injections and then after another 10 injections (20 injections in total). Up to that second DMC meeting all patients have to stay in the hospital for a 2 hours observation; after the analysis of the 20 vaccinations the DMC will review the safety data and may recommend reverting to normal outpatients setting.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Margaret Gralinska | +44 (0) 1323811111 | margot@agirx.co.uk |
Poland | |
WCO (Great Poland Cancer Centre) | Recruiting |
Poznan, Poland, 61-866 |
Study Director: | Margaret Gralinska | AGIRx (Active Gene Interventions) Ltd |
Responsible Party: | AGIRx (active Gene Interventions) Ltd. ( Dr Margaret Gralinska, Executive Director ) |
Study ID Numbers: | AGI - 101H/01-2007 |
Study First Received: | July 15, 2008 |
Last Updated: | July 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00716495 |
Health Authority: | Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products |
Neuroectodermal Tumors Nevus, Pigmented Neoplasms, Germ Cell and Embryonal Neuroepithelioma |
Nevus Neuroendocrine Tumors Melanoma |
Neoplasms Neoplasms by Histologic Type Neoplasms, Nerve Tissue Nevi and Melanomas |